Pharmaceutical compositions comprising meloxicam
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T max of meloxicam of 3 hours or less.
1. A method of treating migraine, comprising administering to a human being in need thereof a combination of a parecoxib, a rizatriptan, a bicarbonate, and a sulfobutylether cyclodextrin (SBEβCD), wherein the human being is suffering from migraine pain or aura.
2. The method of claim 1 , wherein the combination includes a complex of the parecoxib and the SBEβCD.
3. The method of claim 1 , wherein the SBEβCD has 6 to 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.
4. The method of claim 1 , wherein the combination contains about 5 mg to about 30 mg of the rizatriptan free base, or a molar equivalent amount of a salt of rizatriptan.
5. The method of claim 4 , wherein the combination contains about 8 mg to about 13 mg of the rizatriptan free base, or a molar equivalent amount of a salt of rizatriptan.
6. The method of claim 5 , wherein the rizatriptan is present as rizatriptan benzoate.
7. The method of claim 1 , wherein the combination contains about 20 mg to about 40 mg of the parecoxib free acid, or a molar equivalent amount of a salt of parecoxib.
8. The method of claim 7 , wherein the parecoxib is present as parecoxib sodium.
9. The method of claim 1 , wherein the combination contains about 50 mg to about 200 mg of the SBEβCD.
10. The method of claim 1 , wherein the combination contains about 400 mg to about 1000 mg of the bicarbonate.
11. The method of claim 1 , wherein the bicarbonate is sodium bicarbonate.
12. The method of claim 11 , wherein the combination contains about 500 mg of sodium bicarbonate.
13. The method of claim 1 , wherein the human being suffers from migraine pain and aura.
14. The method of claim 1 , wherein the combination is orally administered.
15. The method of claim 2 , wherein the combination contains about 10 mg of the rizatriptan free base, or a molar equivalent amount of a salt of rizatriptan.
16. The method of claim 1 , wherein the human being has moderate to severe migraines.
17. The method of claim 1 , wherein administration of the combination improves the bioavailability of parecoxib.
18. The method of claim 1 , wherein the combination is administered in the form of a tablet or a capsule.
19. The method of claim 1 , wherein administration of the combination reduces migraine pain in the human being.
20. The method of claim 1 , wherein administration of the combination eliminates migraine pain in the human being.
21. The method of claim 1 , wherein administration of the combination reduces the T max of parecoxib.
22. The method of claim 1 , wherein administration of the combination reduces the T max of rizatriptan.
23. The method of claim 1 , wherein the combination further comprises an acid inhibitor.
24. The method of claim 1 , wherein administration of the combination results in faster release or dissolution of parecoxib.
25. The method of claim 1 , wherein administration of the combination results in faster release or dissolution of rizatriptan.